ATE302278T1 - Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen - Google Patents
Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungenInfo
- Publication number
- ATE302278T1 ATE302278T1 AT99905450T AT99905450T ATE302278T1 AT E302278 T1 ATE302278 T1 AT E302278T1 AT 99905450 T AT99905450 T AT 99905450T AT 99905450 T AT99905450 T AT 99905450T AT E302278 T1 ATE302278 T1 AT E302278T1
- Authority
- AT
- Austria
- Prior art keywords
- aur1
- aur2
- polypeptides
- diagnosis
- treatment
- Prior art date
Links
- 101150064299 AUR1 gene Proteins 0.000 title abstract 5
- 101100381333 Arabidopsis thaliana AUR2 gene Proteins 0.000 title abstract 5
- 101100297762 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) PKS12 gene Proteins 0.000 title abstract 5
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/012,135 US6716575B2 (en) | 1995-12-18 | 1998-01-22 | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| PCT/US1999/001283 WO1999037788A2 (en) | 1998-01-22 | 1999-01-21 | Diagnosis and treatment of aur1 and/or aur2 related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE302278T1 true ATE302278T1 (de) | 2005-09-15 |
Family
ID=21753554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99905450T ATE302278T1 (de) | 1998-01-22 | 1999-01-21 | Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6716575B2 (de) |
| EP (1) | EP1051500B1 (de) |
| JP (1) | JP2002508937A (de) |
| AT (1) | ATE302278T1 (de) |
| AU (1) | AU2560599A (de) |
| CA (1) | CA2318352A1 (de) |
| CY (1) | CY1105446T1 (de) |
| DE (1) | DE69926731T2 (de) |
| DK (1) | DK1051500T3 (de) |
| ES (1) | ES2247783T3 (de) |
| WO (1) | WO1999037788A2 (de) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0002477A3 (en) | 1997-08-27 | 2002-09-30 | Pioneer Hi Bred Int | Genes encoding enzymes for lignin biosynthesis and uses thereof |
| JP4590107B2 (ja) | 1999-04-09 | 2010-12-01 | 中外製薬株式会社 | 新規胎児性遺伝子 |
| PL360439A1 (en) * | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AP2003002762A0 (en) * | 2000-09-15 | 2003-03-31 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| AU2002255452B2 (en) * | 2000-12-21 | 2006-06-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP2002236125A (ja) * | 2001-02-06 | 2002-08-23 | Igaku Seibutsugaku Kenkyusho:Kk | タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体 |
| US20030031655A1 (en) * | 2001-02-08 | 2003-02-13 | Sequitur, Inc. | Methods of light activated release of ligands from endosomes |
| US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| WO2003064626A2 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Double-stranded oligonucleotides |
| KR20040084896A (ko) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물 |
| WO2003078427A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
| US20050216961A1 (en) * | 2002-03-28 | 2005-09-29 | Delaney Allen D | Cancer associated protein kinases and their uses |
| US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004013140A1 (en) * | 2002-08-02 | 2004-02-12 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of gsk-3 |
| CA2498000C (en) * | 2002-09-11 | 2015-01-20 | Genentech, Inc. | Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
| US7635770B2 (en) * | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| US7977471B2 (en) * | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
| US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| US7691998B2 (en) * | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
| US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
| US7619081B2 (en) * | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP1570080A4 (de) * | 2002-11-15 | 2006-03-01 | Genomic Health Inc | Genexpressionsprofilierung einer egfr-positiven krebserkrankung |
| MY136174A (en) | 2002-12-24 | 2008-08-29 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| WO2004071572A2 (en) * | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| AU2004213871B9 (en) * | 2003-02-20 | 2009-09-03 | Genomic Health, Inc. | Use of intronic RNA to measure gene expression |
| EP1636380A2 (de) * | 2003-05-30 | 2006-03-22 | Genomic Health, Inc. | Genexpressionsmarker zur reaktion auf egfr-inhibitor-arzneistoffe |
| DK3470535T3 (da) * | 2003-06-24 | 2020-06-29 | Genomic Health Inc | Forudsigelse af sandsynlighed for tilbagevenden af cancer |
| ES2651849T3 (es) * | 2003-07-10 | 2018-01-30 | Genomic Health, Inc. | Algoritmo del perfil de expresión y test para el pronóstico del cáncer |
| EP1678327A4 (de) * | 2003-10-16 | 2007-10-10 | Genomic Health Inc | Qrt-pcr-testsystem zur erstellung von genexpressionsprofilen |
| CN1902193B (zh) * | 2003-12-04 | 2011-07-13 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的喹喔啉 |
| WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| AU2004309396B2 (en) * | 2003-12-23 | 2010-05-13 | Genomic Health, Inc. | Universal amplification of fragmented RNA |
| EP2163650B1 (de) | 2004-04-09 | 2015-08-05 | Genomic Health, Inc. | Genexpressionsmarker zur Vorhersage des Erfolgs von Chemotherapy |
| EP1763524A1 (de) * | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indolderivate und deren verwendung als kinaseinhibitoren |
| US20050260659A1 (en) * | 2004-04-23 | 2005-11-24 | Exagen Diagnostics, Inc. | Compositions and methods for breast cancer prognosis |
| US7605250B2 (en) * | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
| WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| US20050282208A1 (en) * | 2004-06-18 | 2005-12-22 | Cytokinetics, Inc. | Cellular phenotype |
| US7550598B2 (en) * | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| TW200624431A (en) | 2004-09-24 | 2006-07-16 | Hoffmann La Roche | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents |
| US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
| EP1812439B2 (de) * | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
| US7491720B2 (en) * | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
| BRPI0518068A (pt) * | 2004-10-29 | 2008-10-28 | Banyu Pharma Co Ltd | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada |
| EP1815014B1 (de) * | 2004-11-05 | 2012-03-21 | Genomic Health, Inc. | Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung |
| US7930104B2 (en) | 2004-11-05 | 2011-04-19 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
| GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| WO2006055831A2 (en) | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| US20060142247A1 (en) * | 2004-12-17 | 2006-06-29 | Guy Georges | Tricyclic heterocycles |
| ATE409190T1 (de) * | 2005-04-14 | 2008-10-15 | Hoffmann La Roche | Tricyclische azolderivate, ihre herstellung und ihre verwendung als pharmazeutische mittel |
| EP1879894A1 (de) | 2005-04-14 | 2008-01-23 | F.Hoffmann-La Roche Ag | Aminopyrazolderivate, ihre herstellung und verwendung als pharmazeutische mittel |
| EP1860438B1 (de) * | 2005-08-12 | 2009-11-18 | Astellas Pharma Inc. | Verfahren zur identifizierung des zielproteins eines wirkstoffs und verfahren zum screening eines therapeutischen wirkstoffs gegen diabetes mittels des zielproteins |
| US7737151B2 (en) * | 2005-08-18 | 2010-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
| US20070082327A1 (en) * | 2005-09-09 | 2007-04-12 | Cytokinetics, Inc. A Delaware Corporation | Cellular phenotype |
| CA2622352C (en) * | 2005-09-30 | 2014-05-27 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CN101316843B (zh) * | 2005-11-03 | 2013-01-02 | 顶点医药品公司 | 用作激酶抑制剂的氨基嘧啶 |
| BRPI0708850A2 (pt) * | 2006-03-20 | 2011-06-21 | Hoffmann La Roche | derivados de ftalazinona pirazol, sua produção e uso como agentes farmacêuticos |
| EP2001882A1 (de) * | 2006-03-23 | 2008-12-17 | F. Hoffmann-La Roche AG | Substituierte indazolderivate, ihre herstellung und verwendung als pharmazeutische wirkstoffe |
| EP2223925A1 (de) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase-Inhibitoren |
| SG175609A1 (en) | 2006-10-09 | 2011-11-28 | Takeda Pharmaceutical | Kinase inhibitors |
| WO2008057940A1 (en) * | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| NZ577768A (en) * | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| JP5520057B2 (ja) * | 2007-03-09 | 2014-06-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
| ATE526328T1 (de) * | 2007-03-09 | 2011-10-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
| JP2010520887A (ja) * | 2007-03-09 | 2010-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリジン |
| CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| CA2685876A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| JP5389786B2 (ja) * | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害として有用なアミノピリミジン |
| CN101679387A (zh) * | 2007-05-02 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
| WO2008147626A2 (en) * | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| CA2683152A1 (en) * | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| MX2010001137A (es) * | 2007-07-31 | 2010-03-31 | Vertex Pharma | Procesopara preparar 5-fluoro-1h-pirazol[3,4-b]piridin-3-amina y derivados del mismo. |
| WO2010027921A1 (en) * | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
| US9799416B2 (en) * | 2009-11-06 | 2017-10-24 | Terrapower, Llc | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| GB2065653B (en) | 1979-12-19 | 1983-03-09 | Nat Res Dev | Anti-cancer quinazoline derivatives |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| DE3611194A1 (de) | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3920029C2 (de) | 1988-06-30 | 1999-05-20 | Clariant Finance Bvi Ltd | Farbstoffe zum Färben von Kunststoffen |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| WO1991015495A1 (en) | 1990-04-02 | 1991-10-17 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| ES2180535T3 (es) * | 1991-02-22 | 2003-02-16 | American Cyanamid Co | Identificacion de un nuevo gen de tirosina quinasa receptora humana. |
| DK0584222T3 (da) | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
| JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9205320D0 (en) | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
| WO1994003427A1 (en) | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| AU677834B2 (en) | 1993-04-07 | 1997-05-08 | Cancer Research Ventures Limited | Methods for screening of substances for therapeutic activityand yeast for use therein |
| GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5830648A (en) | 1995-05-05 | 1998-11-03 | Sugen, Inc. | Assay and method for transcript imaging |
| AU716330B2 (en) | 1995-12-18 | 2000-02-24 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
-
1998
- 1998-01-22 US US09/012,135 patent/US6716575B2/en not_active Expired - Lifetime
-
1999
- 1999-01-21 JP JP2000528695A patent/JP2002508937A/ja active Pending
- 1999-01-21 DE DE69926731T patent/DE69926731T2/de not_active Expired - Lifetime
- 1999-01-21 DK DK99905450T patent/DK1051500T3/da active
- 1999-01-21 AT AT99905450T patent/ATE302278T1/de active
- 1999-01-21 CA CA002318352A patent/CA2318352A1/en not_active Abandoned
- 1999-01-21 WO PCT/US1999/001283 patent/WO1999037788A2/en not_active Ceased
- 1999-01-21 AU AU25605/99A patent/AU2560599A/en not_active Abandoned
- 1999-01-21 ES ES99905450T patent/ES2247783T3/es not_active Expired - Lifetime
- 1999-01-21 EP EP99905450A patent/EP1051500B1/de not_active Expired - Lifetime
- 1999-03-31 US US09/283,011 patent/US6207401B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 US US09/784,332 patent/US6841579B1/en not_active Expired - Lifetime
-
2005
- 2005-11-15 CY CY20051101394T patent/CY1105446T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1105446T1 (el) | 2010-04-28 |
| WO1999037788A2 (en) | 1999-07-29 |
| US6716575B2 (en) | 2004-04-06 |
| JP2002508937A (ja) | 2002-03-26 |
| US20050002938A1 (en) | 2005-01-06 |
| CA2318352A1 (en) | 1999-07-29 |
| WO1999037788A3 (en) | 1999-09-30 |
| DE69926731D1 (de) | 2005-09-22 |
| EP1051500B1 (de) | 2005-08-17 |
| US6207401B1 (en) | 2001-03-27 |
| EP1051500A2 (de) | 2000-11-15 |
| DE69926731T2 (de) | 2006-05-18 |
| US6841579B1 (en) | 2005-01-11 |
| DK1051500T3 (da) | 2005-12-19 |
| AU2560599A (en) | 1999-08-09 |
| ES2247783T3 (es) | 2006-03-01 |
| US20020081578A1 (en) | 2002-06-27 |
| WO1999037788A9 (en) | 1999-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69926731D1 (de) | Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen | |
| DE69635740D1 (de) | Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen | |
| ATE182180T1 (de) | Lamanin-ketten: diagnostische und therapeutische verwendung | |
| ATE230487T1 (de) | Verfahren zur frühen diagnose von carcinomen | |
| ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
| ATE135371T1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
| DE69334246D1 (de) | Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome | |
| DK0948604T3 (da) | Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet | |
| WO1997048723A3 (en) | Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products | |
| EP1978362A3 (de) | Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität | |
| ATE179712T1 (de) | Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen | |
| DE69934324D1 (de) | Behandlung von entzündungskrankheiten | |
| DE60126248D1 (de) | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs | |
| DE10082504D2 (de) | Indikatorpeptid zur Diagnose und/oder Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen, Antikörperzusammensetzung und immunoassay | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| DE69929683D1 (de) | Antisense modulierung von lfa-3 | |
| ATE312914T1 (de) | Rdgb-proteine | |
| DE60029942D1 (de) | Verwendung von glukose-6-phosphate-isomerase und dagegen gerichteten antikörpern zur diagnose und therapeutischen behandlung von arthritis, und test von zur behandlung der arthritis wirksamen verbindungen | |
| KR880701886A (ko) | 췌장효소원의 유리활성화 펩티드의 면역검정에 의한 질병의 진단, 위중도 예견, 및 모니터링 | |
| DE60020970D1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen | |
| ATE542900T1 (de) | Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs | |
| ATE124722T1 (de) | Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1051500 Country of ref document: EP |